Embedded Files
Our Pipeline
Our Pipeline
Long-Acting Leptin for Anorexia Nervosa
Long-Acting Leptin for Anorexia Nervosa
STATUS: Pre-IND/Manufacturing Development
STATUS: Pre-IND/Manufacturing Development
Our lead program is a long-acting leptin for anorexia nervosa, dosed once weekly. It builds on clinical experience in Germany and Switzerland, where patients treated with off-label metreleptin improved in mood and cognitions within days.
Our Long-Acting Leptin
Our Long-Acting Leptin
Our long-acting leptin is designed for:
Once-weekly dosing
Addressing the immunogenicity of metreleptin
CNS activity, reaching the hypothalamus
Zula holds an exclusive license and agreements for the intellectual property covering the molecule and its use in anorexia nervosa.
Future Programs
Future Programs
STATUS: Research
STATUS: Research
Expanded Indications: Applications for atypical anorexia and eating disorder-associated depression
Amenorrhea Treatment: Addressing hormone-related menstrual disruption in patients with eating disorders and hypothalamic amenorrhea
As a public benefit corporation, Zula is committed to making these treatments accessible and affordable for patients with eating disorders.
As a public benefit corporation, Zula is committed to making these treatments accessible and affordable for patients with eating disorders.
Page updated
Report abuse